Crovalimab

• CAT Number: I041521
• CAS Number: 1917321-26-6
• Purity: ≥95%

Crovalimab（Cat No.:I041521）is an investigational monoclonal antibody designed to target the C5 protein of the complement system, a part of the immune system involved in inflammation and immune responses. By inhibiting C5, crovalimab prevents the activation of the terminal complement pathway, which can contribute to diseases with excessive complement activation, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Crovalimab is being studied as a potential treatment for these and other complement-driven disorders, offering an alternative to existing therapies by providing prolonged efficacy and less frequent dosing.